Severe de novo Ulcerative Colitis following Ixekizumab Therapy

Ixekizumab is a selective monoclonal antibody targeting interleukin-17A, approved for the treatment of chronic plaque psoriasis. It has rarely been associated with inflammatory bowel disease (IBD) in randomized trials only. We report a unique case of severe new-onset ulcerative colitis in a young ma...

Descripción completa

Detalles Bibliográficos
Autores principales: Philipose, Jobin, Ahmed, Moiz, Idiculla, Pretty S., Mulrooney, Stephen M., Gumaste, Vivek V.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: S. Karger AG 2018
Materias:
Single Case
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6244035/
https://www.ncbi.nlm.nih.gov/pubmed/30483039
http://dx.doi.org/10.1159/000493922
Descripción
Sumario:Ixekizumab is a selective monoclonal antibody targeting interleukin-17A, approved for the treatment of chronic plaque psoriasis. It has rarely been associated with inflammatory bowel disease (IBD) in randomized trials only. We report a unique case of severe new-onset ulcerative colitis in a young male complicated by cytomegalovirus infection who was on ixekizumab therapy for plaque psoriasis. We recommend that clinicians should exercise caution before prescribing ixekizumab as it seems to induce and exacerbate IBD.

Ejemplares similares